AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbCellera Biologics Inc. (ABCL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript
AbCellera Biologics Inc. ( ABCL ) Jefferies London Healthcare Conference 2025 November 20, 2025 8:00 AM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Presentation Unknown Analyst Great.
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript
AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Malcolm Hoffman - BMO Capital Markets Equity Research Andrea Tan - Goldman Sachs Group, Inc., Research Division Joshua Nickerson - Stifel, Nicolaus & Company, Incorporated, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Jacqueline Kisa - TD Cowen, Research Division Presentation Operator Good afternoon, and welcome to AbCellera's Third Quarter 2025 Business Update Conference Call.
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.17 per share a year ago.
AbCellera Biologics: Entering Growth Phase After A Pause
AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and ABCL575 entering clinical trials. Despite recent revenue and net income declines due to the business model shift, ABCL is well-funded and expects revenue to double in 2026 as clinical batches commence.
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.
AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chairperson Tryn T.
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.13 per share a year ago.
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ABCELLERA BIOLG (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength?
ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
